[go: up one dir, main page]

WO2000040273A8 - Traitement de maladies virales a l'aide d'un polynucleotide exprimant l'interferon omega - Google Patents

Traitement de maladies virales a l'aide d'un polynucleotide exprimant l'interferon omega

Info

Publication number
WO2000040273A8
WO2000040273A8 PCT/US1999/030843 US9930843W WO0040273A8 WO 2000040273 A8 WO2000040273 A8 WO 2000040273A8 US 9930843 W US9930843 W US 9930843W WO 0040273 A8 WO0040273 A8 WO 0040273A8
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
viral diseases
interferon omega
expressing polynucleotide
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/030843
Other languages
English (en)
Other versions
WO2000040273A2 (fr
WO2000040273A3 (fr
Inventor
Suezanne Parker
Holly Horton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresh Tracks Therapeutics Inc
Original Assignee
Vical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vical Inc filed Critical Vical Inc
Publication of WO2000040273A2 publication Critical patent/WO2000040273A2/fr
Publication of WO2000040273A3 publication Critical patent/WO2000040273A3/fr
Publication of WO2000040273A8 publication Critical patent/WO2000040273A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé permettant de traiter une maladie virale, consistant à administrer à un mammifère une construction polynucléotidique qui comprend un polynucléotide codant pour IFNφ. La construction polynucléotidique de l'invention peut être administrée sans être associée à des agents facilitant la transfection ou sous forme d'un complexe renfermant au moins un ou plusieurs lipides cationiques.
PCT/US1999/030843 1999-01-08 1999-12-28 Traitement de maladies virales a l'aide d'un polynucleotide exprimant l'interferon omega Ceased WO2000040273A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11540399P 1999-01-08 1999-01-08
US60/115,403 1999-01-08

Publications (3)

Publication Number Publication Date
WO2000040273A2 WO2000040273A2 (fr) 2000-07-13
WO2000040273A3 WO2000040273A3 (fr) 2000-11-16
WO2000040273A8 true WO2000040273A8 (fr) 2001-01-11

Family

ID=22361168

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/030843 Ceased WO2000040273A2 (fr) 1999-01-08 1999-12-28 Traitement de maladies virales a l'aide d'un polynucleotide exprimant l'interferon omega

Country Status (1)

Country Link
WO (1) WO2000040273A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001080897A2 (fr) 2000-04-21 2001-11-01 Vical Incorporated Compositions pour l'administration in vivo d'agents therapeutiques derives de polynucleotides et methodes associees
AU2587002A (en) 2000-11-03 2002-05-15 Biomedicines Inc Method for short-term and long-term drug dosimetry
CA2466228A1 (fr) * 2001-11-09 2003-08-07 Biomedicines, Inc. Methode de traitement de maladies faisant appel a l'interferon omega
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
NZ593017A (en) 2006-08-09 2011-08-26 Intarcia Therapeutics Inc Piston assembly for positioning lumen in an osmotic delivery system having groove to retain elastomeric O-ring
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JP2013095755A (ja) * 2011-11-02 2013-05-20 Kyowa Hakko Kirin Co Ltd カチオン性脂質
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
JP6993235B2 (ja) 2015-06-03 2022-01-13 インターシア セラピューティクス，インコーポレイティド インプラントの設置及び撤去システム
EP3733694A1 (fr) 2016-05-16 2020-11-04 Intarcia Therapeutics, Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
JP2023545009A (ja) * 2020-10-02 2023-10-26 イムノン、インコーポレイテッド ポリヌクレオチドワクチンおよびその使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE67786T1 (de) * 1984-08-01 1991-10-15 Boehringer Ingelheim Int Neue genetische sequenzen, die durch sie codierten interferon-peptide vom typ i und diese sie produzierende organismen.
US5641665A (en) * 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents

Also Published As

Publication number Publication date
WO2000040273A2 (fr) 2000-07-13
WO2000040273A3 (fr) 2000-11-16

Similar Documents

Publication Publication Date Title
WO2000040273A8 (fr) Traitement de maladies virales a l'aide d'un polynucleotide exprimant l'interferon omega
HUP9800467A3 (en) Use of hyaluronic acid for producing pharmaceutical compns. for the treatment of interstitial cystitis
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
AU7295601A (en) Treatment of central nervous system diseases by antibodies against glatiramer acetate
WO1996010419A3 (fr) Composition comprenant un virus de recombinaison exprimant un antigene et un virus de recombinaison exprimant une molecule immunostimulatrice
WO1999003508A3 (fr) TRAITEMENT DES MALADIES VASCULAIRES PROLIFERATIVES A L'AIDE DE p27 ET DE SES PROTEINES HYBRIDES
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
EP1758998A4 (fr) Oligoribonucleotides et procedes d'utilisation de ceux-ci dans le traitement d'etats fibreux et d'autres maladies
WO1999002143A3 (fr) Composition contenant un nucleotide
WO2001029175A3 (fr) Modulation antisens de l'expression de fra-1
EP1133997A3 (fr) Traitement de maladies immunes par l'inteferon beta
IL142581A (en) Medicament for treating heart disease
WO1999021538A3 (fr) Utilisation de glycosaminoglycanes pour la fabrication de preparations pharmaceutiques en vue du traitement de maladies des yeux associees au diabete
AU5155700A (en) Gene therapy of pulmonary disease
WO2000043028A3 (fr) Therapie contre une affection cardiaque chronique
WO1994024279A3 (fr) Agents pour la prevention et le traitement de la choree de huntington et d'autres troubles neurologiques
WO2001014415A3 (fr) Gènes egfh2 et produits géniques
AU2002364757A8 (en) Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases
WO2001094570A3 (fr) Procede de transfection
WO2003059334A3 (fr) Gemcitabine pour traiter la variole
WO2003066806A3 (fr) Utilisation therapeutique de composes aziridino
WO2002076405A3 (fr) Compositions et methodes de traitement de maladies ulceratives, de brulures, et d'etats associes
WO2001075021A3 (fr) Nouveau polypeptide, proteine humaine associee au transport de glucose 10, et polynucleotide codant pour ce polypeptide
WO2002038188A3 (fr) Utilisation des promoteurs lrp/mvp humains pour un vecteur inductible par therapie
WO2001068693A8 (fr) Nouveau polypeptide, proteine humaine de reception cannabinoide 7, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: C1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WR Later publication of a revised version of an international search report
122 Ep: pct application non-entry in european phase